Loading...

Biovica announces that the company’s quality system is updated in accordance with  ISO 13485:2016.

Uppsala, Sweden, February 4, 2019. Biovica, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome, announced today that the company has certified their Quality System according to the ISO13485:2016 standard for the development, manufacturing and sale of DiviTum® at the yearly surveillance audit with Biovica’s notified body.  

2019-02-16T00:24:51+00:00 February 4th, 2019 07:57|News|

Biovica carries out a project at Testa Center in order to scale up production to meet expected demand

Uppsala, Sweden, January 31, 2019. The biotech company Biovica, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome, takes the next step in their expansion plan. Biovica will scale up production in the newly built facilities at Testa Center in Uppsala to meet the future demand from customers.

2019-02-16T00:24:51+00:00 January 31st, 2019 09:17|News|

Biovica establishes office in Boston

Biovica opens an office in Boston, the first office in the US. Pontus Nobréus, Business Development Director, will be heading up the office and will be based in Boston from 1st of January 2019.

2019-02-16T00:24:51+00:00 December 4th, 2018 08:00|News|

Biovica to host conference call to provide second quarter 2018/2019 business update

On December 6, 2018, at 08:00 am CET, Biovica International AB (publ) will publish its interim report for the second quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 09:00 am CET. The event will be hosted by Biovica’s CEO Anders Rylander and CFO Cecilia Driving. The presentation will be held in English.

2019-02-16T00:24:51+00:00 November 30th, 2018 11:32|News|

New results suggest that DiviTum® reflects response to palbociclib

New DiviTum® results will be presented at the San Antonio Breast Cancer Symposium, 4-8 December. The data originates from a collaboration with the Prato Hospital, Italy and Baylor College, Houston, US and supports DiviTum® as a biomarker for evaluating effects of a new targeted drug in breast cancer.

2019-02-16T00:24:51+00:00 November 28th, 2018 09:15|News|

Lars Holmqvist to Biovica as Senior Advisor

Lars Holmqvist has been appointed as Senior Advisor to Biovica. He will contribute to Biovica's commercialization strategy and will be very helpful as strategic support for future marketing in the US and Europe.

2019-02-16T00:24:51+00:00 September 28th, 2018 08:00|News|